Event Date: May 06, 2019

There is increasing interest in the use of cannabinoids as a therapeutic intervention in dementia, particularly for agitation. Agitation is a common and persistent symptom in those with Alzheimer’s disease and current pharmacotherapies have modest efficacy and/or poor safety. This session will outline the rationale for use of cannabinoids, review previous literature assessing the efficacy of THC and related compounds for agitation, and present results of the most recent trial of a cannabinoid for agitation. 

Register

Presenter(s):

Krista L. Lanctôt, PhD,
Head, Neuropsychopharmacology Research Program,
Sunnybrook Health Sciences Centre;
Senior Scientist, Sunnybrook Research Institute;
Professor of Psychiatry and Pharmacology, 
University of Toronto
<May 2019>
SunMonTueWedThuFriSat
28
29
30
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
1
2
3
4
5
6
7
8

Cannabis and Dementia: Weeding through the Evidence

There is increasing interest in the use of cannabinoids as a therapeutic intervention in dementia, particularly for agitation. Agitation is a common and persistent symptom in those with Alzheimer’s disease and current pharmacotherapies have modest efficacy and/or poor safety. This session will outline the rationale for use of cannabinoids, review previous literature assessing the efficacy of THC and related compounds for agitation, and present results of the most recent trial of a cannabinoid for agitation. 
Event capacity: N/A
Event location:
Event date: 5/6/2019, 11:00 AM - 12:00 PM